GlassScriptPhysician profile
Sarah Beth Hazelbaker
NPI 1528798873
$1,717.05
in general payments reported to CMS, 2019-2025
14 companies · $41.57 in 2025
The $41.57 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $230 · 2023: $1,172 · 2024: $273 · 2025: $41.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,486.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $432.52 | 2022-2024 | Aristada, Lybalvi, Vivitrol |
| Vanda Pharmaceuticals INC. | $295.55 | 2022-2023 | Hetlioz, Fanapt |
| Abbvie INC. | $189.15 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $178.60 | 2022-2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $173.03 | 2022-2023 | Quviviq |
| Neurocrine Biosciences, INC. | $107.11 | 2023-2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $82.72 | 2022-2023 | Spravato |
| Otsuka America Pharmaceutical, INC. | $75.61 | 2023-2024 | Rexulti, Abilify Maintena |
| Tempus Ai, INC | $64.83 | 2024 | |
| Lundbeck LLC | $37.94 | 2023 | Rexulti |
| Sunovion Pharmaceuticals INC. | $32.53 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $17.95 | 2023 | Austedo |
| E.R. Squibb & Sons, L.L.C. | $15.56 | 2024 | |
| Supernus Pharmaceuticals, INC. | $13.95 | 2024 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Hazelbaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.